Literature DB >> 23475497

Low prevalence of metabolic syndrome and its prediction in Japanese inpatients with schizophrenia.

Yutaro Suzuki1, Takuro Sugai, Naoki Fukui, Junzo Watanabe, Shin Ono, Nobuto Tsuneyama, Mami Saito, Toshiyuki Someya.   

Abstract

OBJECTIVES: There have so far been few papers studying the metabolic syndrome (MetS) prevalence rate in Japanese patients with schizophrenia. We studied the MetS prevalence rate in Japanese controls and inpatients with schizophrenia and compared the prediction factors for the occurrence of MetS.
METHODS: The subjects were 319 inpatients with schizophrenia and 154 controls. The predictive utilities of body mass index (BMI) and the individual components of MetS for MetS diagnosis were evaluated.
RESULTS: The prevalence of MetS did not differ between schizophrenia and control subjects. Subjects with schizophrenia showed higher prevalences of the MetS criteria for high-density lipoprotein cholesterol (HDL) (p < 0.001) and waist circumference (WC) (p < 0.001). In subjects with schizophrenia, the predictive power was found to be highest for HDL, followed by WC, BMI, triglyceride, diastolic blood pressure (BP), systolic BP and fasting plasma glucose. However, in control subjects, the predictive power was found to be highest for triglyceride, followed by WC, systolic BP, BMI, HDL, diastolic BP and fasting plasma glucose. HDL was the component most predictive of MetS in subjects with schizophrenia treated with antipsychotics.
CONCLUSION: Because, in normal clinical practice, it is difficult to obtain temporal measurements for all of the MetS criteria, measurement of HDL may be useful for predicting the MetS.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475497     DOI: 10.1002/hup.2295

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  3 in total

1.  Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Manabu Yamazaki; Kazutaka Shimoda; Takao Mori; Takuro Sugai; Yutaro Suzuki; Toshiyuki Someya
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

2.  The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study.

Authors:  Samer Hammoudeh; Suhaila Ghuloum; Ziyad Mahfoud; Arij Yehya; Abdulmoneim Abdulhakam; Azza Al-Mujalli; Mahmoud Al-Zirie; Mohamed Osman Abdel Rahman; Angela Godwin; Noura Younes; Yahya Hani; Dennis Mook-Kanamori; Marjonneke Mook-Kanamori; Reem El Sherbiny; Hassen Al-Amin
Journal:  BMC Psychiatry       Date:  2018-03-27       Impact factor: 3.630

3.  Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study.

Authors:  Samer Hammoudeh; Hawra Al Lawati; Suhaila Ghuloum; Huma Iram; Arij Yehya; Imen Becetti; Nora Al-Fakhri; Hany Ghabrash; Mena Shehata; Nighat Ajmal; Iman Amro; Hira Safdar; Yassin Eltorki; Hassen Al-Amin
Journal:  Community Ment Health J       Date:  2019-12-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.